← Back to patent-cliff list
YG-1699
Tier C — Watch / tradeYG-1699
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SGLT2, SGLT1
Indications (approved)：Type 1 diabetes, Diabetes, Type 2 diabetes, Chronic renal impairment, Heart failure, Cystic fibrosis
Regional status
US
Phase II
2021-06-17
EU
-
China
Phase II
2024-04-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of YG-1699?
Approved indications include: Type 1 diabetes, Diabetes, Type 2 diabetes, Chronic renal impairment, Heart failure, Cystic fibrosis.
When does the YG-1699 patent expire?
No public expiry year is available for YG-1699 yet; this page updates once verified.
How do I get a quote for YG-1699 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06